Binding Term Sheet for the intended issuance of a convertible bond to the European Investment Bank (EIB) signed – Biotech Investments

Korneuburg, Austria, 27. November 2024 – Marinomed Biotech AG (the “Company”) announces that it has signed a binding term sheet with the European Investment Bank (EIB) for the intended issuance of a convertible bond (registered bond in the name or order) with a nominal value of EUR 423,840, which is to be subscribed exclusively by the European Investment Bank (EIB) (excluding the statutory subscription rights of existing shareholders) against the contribution of a right of segregation. The convertible bond will evidence a conversion right in initially up to 84,768 shares of the Company at a conversion price of EUR 5 per share and will be issued in December 2024. In the event of conversion of the convertible bond, it is intended to issue the shares available from the conditional capital of the Company. A corresponding report on the planned exclusion of the statutory subscription rights of existing shareholders to convertible bonds will be published shortly. The required resolution of the Supervisory Board on the issuance of the convertible bond with the exclusion of subscription rights can be adopted at the earliest two weeks after publication of the report. The necessary consent of the insolvency administrator for the issuance of the convertible bond has not yet been obtained. 

+++ End of ad-hoc announcement +++